Search clinical trials for: Prophylaxis in Factor VII Deficiency

Total 457794 results

PedNet Haemophilia Research Foundation
Lund University Hospital

Recruiting

The European Paediatric Network for Haemophilia Management ( PedNet Registry) (PedNet)

Factor IX Deficiency | Factor VIII Deficiency

Norway, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
MRC/UVRI and LSHTM Uganda Research Unit
King's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaborators

Enrolling by invitation

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

HIV Infections

Uganda
Spark Therapeutics

Completed

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Blood Coagulation Disorder | Factor VIII Deficiency

United States, Australia, Thailand, Canada
Baxalta now part of Shire

Completed

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS (SPACE)

Hemophilia A | Hemophilia B

United States
University of Colorado, Denver
The University of Texas Health Science Center, Houston; Bayer; Emory University; Rush University Medical Center and other collaborators

Completed

Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency (JOSC)

Hemophilia
St. James's Hospital, Ireland
Baxter BioScience

Unknown

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens (PERSONAL)

Severe Haemophilia A

Ireland
University of L'Aquila
TRIB s.r.l.

Completed

Treatment of Inherited Factor VII Deficiency (STER)

Factor VII Deficiency

Italy
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Bayer

Recruiting

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Hemophilia A | Prophylaxis of Bleeding | Treatment of Bleeding

Korea, Republic of
ViiV Healthcare
GlaxoSmithKline; PPD

Not yet recruiting

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) (PALISADE)

HIV Infections

Brazil, Argentina, Peru, Botswana, Kenya, Malawi, South Africa, Thailand, Uganda, Vietnam, Zimbabwe
Amany Keruakous, MD, MS.

Not yet recruiting

VitD3 Supplementation in Patients With Multiple Myeloma

Multiple Myeloma

United States
Bayer

Recruiting

An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A (JOIHA)

Hemophilia A | Prophylaxis of Bleeding

Italy
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
Pfizer

Recruiting

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B (BASIS KIDS)

Hemophilia A | Hemophilia B

Denmark, Taiwan, Canada, Turkey, Spain, China, United Kingdom, South Africa, Saudi Arabia, Israel, Korea, Republic of, Austria, Germany, Japan, Australia, Italy, India, Slovakia, France, United States, Brazil, Argentina
University of Toronto
ViiV Healthcare

Not yet recruiting

HIV Self-Testing and Comic Intervention With Refugee Adolescents and Youth

HIV Infections | HIV/AIDS | Knowledge, Attitudes, Practice

Canada
Bayer

Recruiting

Prophylaxis Regimen for Hemophilia A Patients (PREDICT)

Hemophilia A | Prophylaxis of Bleeding

United States
Wayne State University
Genentech, Inc.

Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis (STEP)

Hemophilia A

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome

Cytokine Release Syndrome | Stem Cell Transplant Complications

Mexico
Indiana Hemophilia &Thrombosis Center, Inc.
Genentech, Inc.

Recruiting

Hemlibra in Mild Hemophilia A

Factor VIII Deficiency, Congenital

United States
Brown University
National Institute on Drug Abuse (NIDA); University of California, San Diego; Beth Israel Deaconess Medical Center and other collaborators

Recruiting

Pre-exposure Prophylaxis (PrEP) for Health (PrEP)

Substance Dependence | HIV (Human Immunodeficiency Virus)

United States
American Thrombosis and Hemostasis Network
Sanofi; Pfizer; Genentech, Inc.; CSL Behring; Hemophilia of Georgia, Inc.; Hemab Therapeutics

Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hemophilia | Thrombosis | Thrombophilia | Sickle Cell Disease | Thalassemia | Bleeding Disorder | Von Willebrand Diseases | Factor IX Deficiency | Connective Tissue Disorder | Factor VIII Deficiency | Hematologic Disorder | Rare Bleeding Disorder | Platelet Disorder

United States
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
Washington Institute for Coagulation
Genentech, Inc.

Recruiting

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (EmiMSK)

Hemophilia A

United States
Brugmann University Hospital

Recruiting

Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?

Hemophilia

Belgium
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

Hemophilia A | Children | Prophylaxis of Bleeding | Treatment of Bleeding

Canada, United States, Brazil, Italy, Turkey, Argentina, Norway
Boston University
National Institute of Mental Health (NIMH); Massachusetts General Hospital; New... and other collaborators

Active, not recruiting

Supporting Sustained HIV Treatment Adherence After Initiation (SUSTAIN)

HIV Infections | Adherence, Medication

South Africa
Pfizer

Active, not recruiting

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Hemophilia A | Hemophilia B

United States, Spain, Canada, China, Korea, Republic of, Hong Kong, Serbia, Taiwan, Turkey, France, Oman, Saudi Arabia, Japan, India, South Africa, Mexico, Croatia, Italy, Bulgaria, Russian Federation
RTI International
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Enrolling by invitation

Early Check: Expanded Screening in Newborns

Primary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditions

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Spark Therapeutics

Completed

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Hematologic Diseases | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Gene Therapy | Blood Coagulation Disorder | Gene Transfer | Adeno-Associated Virus (AAV) | Factor VIII (FVIII) | Factor VIII (FVIII)... and other conditions

United States
ViiV Healthcare

Active, not recruiting

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PILLAR)

HIV Infections

United States
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa
Bayer

Completed

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)

Hemophilia A

Korea, Republic of, Taiwan, Turkey, Singapore, United States, Netherlands, Austria, Denmark, United Kingdom, Belgium, Italy, France, Japan, Germany, Israel, Poland, Canada, Norway, Romania, Colombia
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Octapharma

Completed

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Von Willebrand Diseases

Lebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine
Groupe Maladies hémorragiques de Bretagne

Completed

Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A (GIDEHAC)

Factor VIII Deficiency | Desmopressin | Carrier of Hemophilia A

France
Grifols Biologicals, LLC

Active, not recruiting

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Von Willebrand Disease
Jiangsu Gensciences lnc.

Completed

A Phase I of SS109 in Hemophilia A or and B With Inhibitors

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Spanish Society of Thrombosis and Haemostasis
Takeda; Instituto de Investigación Hospital Universitario La Paz

Completed

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

Hemophilia A | Hemophilia | Factor VIII Deficiency

Spain
Bioverativ, a Sanofi company

Completed

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1)

Factor VIII Deficiency

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
Ipsen

Terminated

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Insulin-like Growth Factor-1 Deficiency

United States
Chulalongkorn University

Completed

Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Hemophilia

Thailand
Genzyme, a Sanofi Company

Completed

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (ATLAS-PPX)

Hemophilia

United States, Australia, China, Denmark, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Turkey, Ukraine, United Kingdom, Mexico
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
French National Agency for Research on AIDS and...
Centre Hospitalier Universitaire Dijon; University Hospital, Montpellier; University... and other collaborators

Completed

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

Virus-HIV

France
Chulalongkorn University

Completed

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Severe Hemophilia A Without Inhibitor

Thailand
Hoffmann-La Roche

Completed

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (POWER)

Haemophilia A | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor | Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor

Italy

Search clinical trials for: Prophylaxis in Factor VII Deficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations